Physician profile
Ralph E Morales
NPI 1861575573
$1,406.58
in general payments reported to CMS, 2019-2025
23 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.82 · 2020: $193 · 2021: $32.50 · 2022: $351 · 2023: $210 · 2024: $180 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $441.36 | 2019-2023 | Jot Dx |
| Novo Nordisk INC | $164.95 | 2022-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $98.94 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $87.47 | 2024-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $72.52 | 2023-2025 | Verquvo |
| Boston Scientific Corporation | $68.99 | 2022 | |
| Zoll Respicardia, INC. | $61.58 | 2025 | Remede System |
| Janssen Pharmaceuticals, INC | $47.75 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.15 | 2023-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $44.92 | 2019-2020 | |
| Pfizer INC. | $31.57 | 2025 | |
| Organogenesis INC. | $29.73 | 2022 | |
| Alnylam Pharmaceuticals INC. | $27.12 | 2023 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $23.61 | 2024 | Arcalyst |
| Ucb, INC. | $22.66 | 2025 | Briviact |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.49 | 2025 | Jardiance |
| Neurelis, INC. | $22.11 | 2025 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $17.56 | 2024 | Eliquis |
| Tactile Systems Technology INC | $16.10 | 2023 | Entre Plus, Flexitouch Plus |
| Astrazeneca Pharmaceuticals Lp | $15.13 | 2023 | Farxiga |
| Terumo Medical Corporation | $14.77 | 2023 | Angio-Seal |
| Inspire Medical Systems, INC. | $14.59 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $14.51 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.